Analysts’ Top Healthcare Picks: Orchestra BioMed Holdings (OBIO), Cardinal Health (CAH)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Orchestra BioMed Holdings (OBIO – Research Report), Cardinal Health (CAH – Research Report) and Healthequity (HQY – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Orchestra BioMed Holdings (OBIO)
In a report released today, Matt Miksic from Barclays maintained a Buy rating on Orchestra BioMed Holdings, with a price target of $12.00. The company’s shares closed last Tuesday at $4.61.
According to TipRanks.com, Miksic is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Orchestra BioMed Holdings with a $13.40 average price target, representing a 188.8% upside. In a report issued on March 12, Chardan Capital also maintained a Buy rating on the stock with a $20.00 price target.
See the top stocks recommended by analysts >>
Cardinal Health (CAH)
In a report released yesterday, Glen Santangelo from Barclays reiterated a Buy rating on Cardinal Health. The company’s shares closed last Tuesday at $216.36.
According to TipRanks.com, Santangelo is a 4-star analyst with an average return of
Cardinal Health has an analyst consensus of Strong Buy, with a price target consensus of $250.50.
Healthequity (HQY)
Barclays analyst Peter Warendorf maintained a Buy rating on Healthequity today and set a price target of $110.00. The company’s shares closed last Tuesday at $79.40.
According to TipRanks.com, Warendorf is a 1-star analyst with an average return of
Currently, the analyst consensus on Healthequity is a Moderate Buy with an average price target of $110.60, representing a 38.9% upside. In a report issued on March 5, KeyBanc also maintained a Buy rating on the stock with a $125.00 price target.
